You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Imbruvica

Showing 1 - 25 of 146
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Breast Tumors, Malignant Tumor of Breast Trial in Dallas (Trastuzumab, Ibrutinib 560 mg, Ibrutinib 840 mg)

Recruiting
  • Breast Neoplasms
  • Malignant Neoplasm of Breast
  • Dallas, Texas
    10 sites incl TX, WA, VA, and NV
May 16, 2022

Head Neck Cancer, Squamous Cell Carcinoma of the Head and Neck Trial in La Jolla (Ibrutinib 560mg PO daily (Imbruvica),

Active, not recruiting
  • Head and Neck Cancer
  • Squamous Cell Carcinoma of the Head and Neck
  • Ibrutinib 560mg PO daily (Imbruvica)
  • +2 more
  • La Jolla, California
    UCSD Moores Cancer Center
Jan 11, 2023

B-cell Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Mantle Cell Lymphoma Trial in United States (Cirmtuzumab (2-16

Recruiting
  • B-cell Chronic Lymphocytic Leukemia
  • +3 more
  • Cirmtuzumab (2-16 kg/mg) plus Ibrutinib
  • +5 more
  • Duarte, California
  • +12 more
Jun 16, 2022

Leukemia, Lymphocytic, Chronic, B-Cell, Small Lymphocytic Lymphoma Trial (Ibrutinib, Venetoclax)

Not yet recruiting
  • Leukemia, Lymphocytic, Chronic, B-Cell
  • Small Lymphocytic Lymphoma
  • (no location specified)
Jul 19, 2023

Diffuse Large B Cell Lymphoma Trial in Berlin (Ibrutinib and Bortezomib + R-CHOP)

Active, not recruiting
  • Diffuse Large B Cell Lymphoma
  • Ibrutinib and Bortezomib + R-CHOP
  • Berlin, Germany
    Charité - Universitätsmedizin Berlin, Hematology, Oncology and T
Aug 10, 2022

Mantle Cell Lymphoma Refractory Trial (Ibrutinib, Venetoclax, Navitoclax)

Not yet recruiting
  • Mantle Cell Lymphoma Refractory
  • (no location specified)
May 16, 2023

Glioblastoma Trial in Cleveland (Ibrutinib, Radiation, Temozolomide (TMZ))

Active, not recruiting
  • Glioblastoma
  • Cleveland, Ohio
    Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Ca
Jan 30, 2023

Recurrent Chronic Lymphoid Leukemia Trial in Boston (ACY-1215, Ibrutinib, Idelalisib)

Active, not recruiting
  • Recurrent Chronic Lymphoid Leukemia
  • Boston, Massachusetts
    Dana Farber Cancer Institute
Dec 19, 2022

Mantle Cell Lymphoma Trial in Houston (Ibrutinib)

Recruiting
  • Mantle Cell Lymphoma
  • Houston, Texas
    M D Anderson Cancer Center
Nov 1, 2022

Malignant Tumors Stated as Primary Lymphoid Haematopoietic, Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia Trial in

Active, not recruiting
  • Malignant Neoplasms Stated as Primary Lymphoid Haematopoietic
  • +2 more
  • Houston, Texas
    University of Texas MD Anderson Cancer Center
Jan 20, 2023

Waldenstrom's Macroglobulinemia Trial in Boston (Ibrutinib)

Completed
Has Results
  • Waldenstrom's Macroglobulinemia
  • Boston, Massachusetts
  • +1 more
Dec 5, 2022

Mantle-Cell Lymphoma Trial in United States (Ixazomib, Ibrutinib)

Active, not recruiting
  • Mantle-Cell Lymphoma
  • Atlanta, Georgia
  • +13 more
Nov 17, 2022

Waldenstrom's Macroglobulinemia Trial in Boston (Ulocuplumab, Ibrutinib)

Active, not recruiting
  • Waldenstrom's Macroglobulinemia
  • Boston, Massachusetts
    Dana Farber Cancer Institute
Jun 20, 2022

CNS B-Cell Non-Hodgkin Lymphoma, Recurrent CNS Lymphoma, Refractory CNS Lymphoma Trial in Houston (Ibrutinib, Nivolumab)

Recruiting
  • Central Nervous System B-Cell Non-Hodgkin Lymphoma
  • +2 more
  • Houston, Texas
    M D Anderson Cancer Center
Dec 13, 2022

Chronic Lymphocytic Leukemia Trial in Houston (Ibrutinib, Venetoclax)

Recruiting
  • Chronic Lymphocytic Leukemia
  • Houston, Texas
    M D Anderson Cancer Center
Sep 21, 2022

Chronic Lymphocytic Leukemia (CLL) Trial in Boston (Ibrutinib, Copanlisib, Acalabrutinib)

Recruiting
  • Chronic Lymphocytic Leukemia (CLL)
  • Boston, Massachusetts
    Dana-Farber Cancer Institute
May 13, 2022

CNS Lymphoma Trial in Petah Tikva (Imbruvica)

Recruiting
  • Central Nervous System Lymphoma
  • Imbruvica
  • Petah Tikva, Israel
    Hematology Institute
May 9, 2022

Chronic Lymphocytic Leukemia Trial in Milano (Ibrutinib and obinutuzumab)

Recruiting
  • Chronic Lymphocytic Leukemia
  • Ibrutinib and obinutuzumab
  • Milano, MI, Italy
    Strategic Research Program on CLL
Apr 2, 2022

Colon Cancer, Colorectal Cancer, Colorectal Carcinoma Trial in Tampa (Pembrolizumab, Ibrutinib)

Completed
Has Results
  • Colon Cancer
  • +3 more
  • Tampa, Florida
    H. Lee Moffitt Cancer Center and Research Institute
Jun 1, 2022

Waldenstrom Macroglobulinemia, MYD88 Gene Mutation Trial in Boston (IBRUTINIB, Venetoclax)

Active, not recruiting
  • Waldenstrom Macroglobulinemia
  • MYD88 Gene Mutation
  • Boston, Massachusetts
  • +1 more
Apr 1, 2022

Small Lymphocytic Leukemia (SLL), Chronic Lymphocytic Leukemia (CLL) Trial run by the NHLBI (Duvelisib, Ibrutinib)

Terminated
Has Results
  • Small Lymphocytic Leukemia (SLL)
  • Chronic Lymphocytic Leukemia (CLL)
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Feb 15, 2022

Metastatic Melanoma, Stage III Cutaneous Melanoma AJCC v7, Stage IIIA Cutaneous Melanoma AJCC v7 Trial in Rochester (drug,

Active, not recruiting
  • Metastatic Melanoma
  • +6 more
  • Rochester, Minnesota
    Mayo Clinic in Rochester
Jan 13, 2023

Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Mantle Cell Lymphoma Trial in United States (TGR-1202, Ibrutinib)

Active, not recruiting
Has Results
  • Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
  • Mantle Cell Lymphoma
  • Monterey, California
  • +4 more
Aug 29, 2022

Chronic Lymphocytic Leukemia, Recurrent Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma Trial in Houston

Active, not recruiting
  • Chronic Lymphocytic Leukemia
  • +5 more
  • Houston, Texas
    M D Anderson Cancer Center
Oct 12, 2022

Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma Trial run by the NHLBI (Ibrutinib, Fludarabine)

Active, not recruiting
Has Results
  • Chronic Lymphocytic Leukemia
  • Small Lymphocytic Lymphoma
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Mar 1, 2022